Biotech | February 28, 2026
Synthekine teams up with Merck to test breakthrough lung cancer combo
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
The NDA filing is supported by results from the phase III evERA Breast Cancer study
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease
Subscribe To Our Newsletter & Stay Updated
